<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00283400</url>
  </required_header>
  <id_info>
    <org_study_id>R01NS049135</org_study_id>
    <secondary_id>R01NS049135</secondary_id>
    <nct_id>NCT00283400</nct_id>
  </id_info>
  <brief_title>Treatment of Subarachnoid Hemorrhage With Human Albumin</brief_title>
  <official_title>Treatment of Subarachnoid Hemorrhage With Human Albumin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the tolerability and safety of 25 percent human
      albumin therapy in patients with subarachnoid hemorrhage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An estimated 37,500 people in the United States have subarachnoid hemorrhage (SAH) every
      year. SAH is usually secondary to a brain aneurysm that has burst. In SAH the bleeding
      accumulates around the lining of the brain. SAH is associated with a 51percent mortality
      rate, and one third of survivors are left functionally dependent. Cerebral vasospasm, which
      is a delayed narrowing of the cerebral arteries following SAH, has been identified as the
      most important reason for neurological deterioration and bad outcome in cases of SAH.
      Cerebral vasospasm may be caused by multiple mechanisms.

      Treatment with a neuroprotective agent, such as human albumin (HA), may be beneficial for
      prevention of cerebral vasospasm and improved clinical outcome in patients with SAH. HA is a
      major protein found in blood and is responsible for maintaining fluid balance in the vascular
      system (blood vessels). The purpose of this study was to determine the safety and
      tolerability of 25 percent HA therapy in patients with SAH. This open-label, dose-escalation
      study will provide necessary information for a future definitive phase III clinical trial on
      the efficacy of treatment with HA in patients with SAH.

      The study was designed to enroll 80 patients at 5 centers in the US. Patients with eligible
      SAH first underwent surgical or endovascular repair, which was considered standard care.
      Endovascular repair was a repair of the aneurysm from the inside of the blood vessel.

      Following neurosurgical or endovascular treatment, participants were given a daily infusion
      of HA for 7 days. The HA dose was allocated as follows: the first tier (20 patients) would
      receive 0.625 grams (g) of HA per kilogram (kg) of body weight; patients in the second tier
      would receive 1.25g of HA per kg; patients in the third tier would receive 1.875g of HA per
      kg; and patients in the fourth tier would receive 2.5g of HA per kg. Safety and tolerability
      was evaluated by the Data and Safety Monitoring Board (DSMB) after each tier was completed
      and before the study advanced to the next dose tier. A specific safety threshold for
      congestive heart failure and other adverse events was defined based on data from previous
      studies.

      In the follow-up phase, patients participated in study-related evaluations of their health at
      15 days and three months. Duration of the study for participants was 90 days.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study met safety endpoints
  </why_stopped>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of the 25% Human Albumin Dosages and the Functional Outcome.</measure>
    <time_frame>9 days after enrollment</time_frame>
    <description>Tolerability outcome: Subject's ability to receive the full allocated human albumin dose without incurring frank congestive heart failure or experiencing anaphylactic reactions that required discontinuation of the treatment. Study would be terminated if 2 or more subjects developed severe or life-threatening heart failure considered to be related (probably, possibly, and definitely) to albumin treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>within 3 months after enrollment</time_frame>
    <description>Serious adverse events included neurological and medical complications and neurological deterioration.
Neurological deterioration was defined as a decline by more than 2 points in the Glasgow Coma Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Good Clinical Outcome Was Defined as a Glasgow Outcome Scale Score of 0-1</measure>
    <time_frame>3 months after enrollment</time_frame>
    <description>Number of subjects with good clinical outcome defined as a Glasgw Outcome Scale score of 0-1</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Subarachnoid Hemorrhage</condition>
  <arm_group>
    <arm_group_label>dosage tier 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.625 g/kg 25% human albumin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dosage tier 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.25 g/kg 25% human albumin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dosage tier 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.875 g/kg 25% human albumin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dosage tier 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2.5 g/kg 25% human albumin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>25% human albumin</intervention_name>
    <description>25% human albumin: after approval by the Data and Safety Monitoring Board dosage tier would be escalated to the subsequent higher level sequentially.</description>
    <arm_group_label>dosage tier 1</arm_group_label>
    <arm_group_label>dosage tier 2</arm_group_label>
    <arm_group_label>dosage tier 3</arm_group_label>
    <arm_group_label>dosage tier 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients (male or female) were at least 18 but younger than 80 years of age.

          -  Onset of new neurological signs of subarachnoid hemorrhage within 72 hours at the time
             of evaluation and initiation of treatment with 25% human albumin.

          -  Clinical signs consistent with the diagnosis of subarachnoid hemorrhage including
             severe thunderclap headache, cranial nerve abnormalities, decreased level of
             consciousness, meningismus and focal neurological deficits.

          -  Computed tomography demonstrated subarachnoid hemorrhage.

          -  Cerebral angiography revealed the presence of saccular aneurysm(s) in a location that
             explains the subarachnoid hemorrhage.

          -  Treatment of cerebral aneurysm was carried out prior to initiation of HA infusion but
             within 72 hours of symptom onset. Accepted treatments of aneurysms include surgical
             clipping or endovascular embolization.

        Exclusion Criteria:

          -  Time of symptom onset could be reliably assessed.

          -  No demonstrable aneurysm by cerebral angiography.

          -  Evidence of traumatic, mycotic, or fusiform aneurysm by cerebral angiography.

          -  World Federation of Neurological Surgeons scale of IV and V

          -  Computed tomography scale of 0-1

          -  History within the past 6 months, and/or physical findings on admission of
             decompensated congestive heart failure (NYHA Class IV or congestive heart failure
             requiring hospitalization).

          -  Patient received albumin prior to treatment assignment during the present admission.

          -  Hospitalization for or diagnosis of acute myocardial infarction within the preceding 3
             months.

          -  Symptoms or electrocardiographic signs indicative of acute myocardial infarction on
             admission.

          -  Electrocardiographic evidence and/or physical findings compatible with second- or
             third-degree heart block, or of cardiac arrhythmia associated with hemodynamic
             instability.

          -  Echocardiogram performed before treatment revealing a left ventricular ejection
             fraction â‰¤ 40% (if available).

          -  Serum creatinine &gt; 2.0 mg/dl or creatinine clearance &lt; 50 ml/min.

          -  Pregnancy, lactation or parturition within previous 30 days.

          -  Allergy to albumin.

          -  Severe prior physical disability that precludes evaluation of clinical outcome
             measures.

          -  History of chronic lung disease

          -  Current participation in another drug treatment protocol.

          -  Severe terminal disease with life expectancy less than 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose I. Suarez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State University</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Data Coordination Unit, Department of Biostatistics, Bioinformatics and Epidemiology, at the Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Suarez JI, Shannon L, Zaidat OO, Suri MF, Singh G, Lynch G, Selman WR. Effect of human albumin administration on clinical outcome and hospital cost in patients with subarachnoid hemorrhage. J Neurosurg. 2004 Apr;100(4):585-90.</citation>
    <PMID>15070109</PMID>
  </reference>
  <reference>
    <citation>Suarez JI, Qureshi AI, Yahia AB, Parekh PD, Tamargo RJ, Williams MA, Ulatowski JA, Hanley DF, Razumovsky AY. Symptomatic vasospasm diagnosis after subarachnoid hemorrhage: evaluation of transcranial Doppler ultrasound and cerebral angiography as related to compromised vascular distribution. Crit Care Med. 2002 Jun;30(6):1348-55.</citation>
    <PMID>12072693</PMID>
  </reference>
  <reference>
    <citation>Lennihan L, Mayer SA, Fink ME, Beckford A, Paik MC, Zhang H, Wu YC, Klebanoff LM, Raps EC, Solomon RA. Effect of hypervolemic therapy on cerebral blood flow after subarachnoid hemorrhage : a randomized controlled trial. Stroke. 2000 Feb;31(2):383-91.</citation>
    <PMID>10657410</PMID>
  </reference>
  <reference>
    <citation>Haley EC Jr, Kassell NF, Torner JC. A randomized controlled trial of high-dose intravenous nicardipine in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg. 1993 Apr;78(4):537-47.</citation>
    <PMID>8450326</PMID>
  </reference>
  <reference>
    <citation>Wilkes MM, Navickis RJ. Patient survival after human albumin administration. A meta-analysis of randomized, controlled trials. Ann Intern Med. 2001 Aug 7;135(3):149-64.</citation>
    <PMID>11487482</PMID>
  </reference>
  <reference>
    <citation>Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R; SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004 May 27;350(22):2247-56.</citation>
    <PMID>15163774</PMID>
  </reference>
  <reference>
    <citation>Belayev L, Liu Y, Zhao W, Busto R, Ginsberg MD. Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke. 2001 Feb;32(2):553-60.</citation>
    <PMID>11157196</PMID>
  </reference>
  <reference>
    <citation>Osterloh K, Ewert U, Pries AR. Interaction of albumin with the endothelial cell surface. Am J Physiol Heart Circ Physiol. 2002 Jul;283(1):H398-405.</citation>
    <PMID>12063314</PMID>
  </reference>
  <reference>
    <citation>Zhang WJ, Frei B. Albumin selectively inhibits TNF alpha-induced expression of vascular cell adhesion molecule-1 in human aortic endothelial cells. Cardiovasc Res. 2002 Sep;55(4):820-9.</citation>
    <PMID>12176131</PMID>
  </reference>
  <results_reference>
    <citation>Suarez JI, Martin RH, Calvillo E, Dillon C, Bershad EM, Macdonald RL, Wong J, Harbaugh R; ALISAH Investigators. The Albumin in Subarachnoid Hemorrhage (ALISAH) multicenter pilot clinical trial: safety and neurologic outcomes. Stroke. 2012 Mar;43(3):683-90. doi: 10.1161/STROKEAHA.111.633958. Epub 2012 Jan 19.</citation>
    <PMID>22267829</PMID>
  </results_reference>
  <results_reference>
    <citation>Suarez JI, Martin RH, Calvillo E, Bershad EM, Venkatasubba Rao CP. Effect of human albumin on TCD vasospasm, DCI, and cerebral infarction in subarachnoid hemorrhage: the ALISAH study. Acta Neurochir Suppl. 2015;120:287-90. doi: 10.1007/978-3-319-04981-6_48.</citation>
    <PMID>25366638</PMID>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2006</study_first_submitted>
  <study_first_submitted_qc>January 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2006</study_first_posted>
  <results_first_submitted>February 5, 2013</results_first_submitted>
  <results_first_submitted_qc>March 18, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 1, 2015</results_first_posted>
  <last_update_submitted>March 18, 2015</last_update_submitted>
  <last_update_submitted_qc>March 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Jose I. Suarez</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>subarachnoid hemorrhage</keyword>
  <keyword>SAH</keyword>
  <keyword>human albumin</keyword>
  <keyword>HA</keyword>
  <keyword>cerebral vasospasm</keyword>
  <keyword>aneurysm</keyword>
  <keyword>neuroprotective</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The National Institutes of Health funded the Albumin in Subarachnoid Hemorrhage (ALISAH) pilot study, initiated in May 2006 and terminated in May 2010. The study was originally planned for 3 years but mostly due to the principal investigators transferring institutions and initiation of 2 non-US sites, 1 extra year was needed.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Dosage Tier 1</title>
          <description>25% human albumin 0.625 g/kg</description>
        </group>
        <group group_id="P2">
          <title>Dosage Tier 2</title>
          <description>25% human albumin 1.25 g/kg</description>
        </group>
        <group group_id="P3">
          <title>Dosage Tier 3</title>
          <description>25% human albumin 1.875 g/kg</description>
        </group>
        <group group_id="P4">
          <title>Dosage Tier 4</title>
          <description>25% human albumin2.5 g/kg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dosage Tier 1</title>
          <description>25% human albumin 0.625 g/kg</description>
        </group>
        <group group_id="B2">
          <title>Dosage Tier 2</title>
          <description>25% human albumin 1.25 g/kg</description>
        </group>
        <group group_id="B3">
          <title>Dosage Tier 3</title>
          <description>25% human albumin 1.875 g/kg</description>
        </group>
        <group group_id="B4">
          <title>Dosage Tier 4</title>
          <description>25% human albumin 2.5 g/kg</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="0"/>
            <count group_id="B5" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B5" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51" spread="25"/>
                    <measurement group_id="B2" value="51" spread="24"/>
                    <measurement group_id="B3" value="55" spread="25"/>
                    <measurement group_id="B5" value="51" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B5" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B5" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of the 25% Human Albumin Dosages and the Functional Outcome.</title>
        <description>Tolerability outcome: Subject's ability to receive the full allocated human albumin dose without incurring frank congestive heart failure or experiencing anaphylactic reactions that required discontinuation of the treatment. Study would be terminated if 2 or more subjects developed severe or life-threatening heart failure considered to be related (probably, possibly, and definitely) to albumin treatment.</description>
        <time_frame>9 days after enrollment</time_frame>
        <population>Sample size consideration for this Phase I dose-escalation study was based on the feasibility of recruiting patients in a 3-year study period at 5 sites.The recruitment yield would be a maximum of 80 patients or 20 patients per dosage group. Statistical analyses were mainly descriptive.</population>
        <group_list>
          <group group_id="O1">
            <title>Dosage Tier 1</title>
            <description>25% human albumin 0.625 g/kg</description>
          </group>
          <group group_id="O2">
            <title>Dosage Tier 2</title>
            <description>25% human albumin 1.25 g/kg</description>
          </group>
          <group group_id="O3">
            <title>Dosage Tier 3</title>
            <description>25% human albumin 1.875 g/kg</description>
          </group>
          <group group_id="O4">
            <title>Dosage Tier 4</title>
            <description>25% human albumin 2.5 g/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of the 25% Human Albumin Dosages and the Functional Outcome.</title>
          <description>Tolerability outcome: Subject's ability to receive the full allocated human albumin dose without incurring frank congestive heart failure or experiencing anaphylactic reactions that required discontinuation of the treatment. Study would be terminated if 2 or more subjects developed severe or life-threatening heart failure considered to be related (probably, possibly, and definitely) to albumin treatment.</description>
          <population>Sample size consideration for this Phase I dose-escalation study was based on the feasibility of recruiting patients in a 3-year study period at 5 sites.The recruitment yield would be a maximum of 80 patients or 20 patients per dosage group. Statistical analyses were mainly descriptive.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Adverse Events</title>
        <description>Serious adverse events included neurological and medical complications and neurological deterioration.
Neurological deterioration was defined as a decline by more than 2 points in the Glasgow Coma Scale.</description>
        <time_frame>within 3 months after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dosage Tier 1</title>
            <description>25% human albumin 0.625 g/kg</description>
          </group>
          <group group_id="O2">
            <title>Dosage Tier 2</title>
            <description>25% human albumin 1.25 g/kg</description>
          </group>
          <group group_id="O3">
            <title>Dosage Tier 3</title>
            <description>25% human albumin 1.875 g/kg</description>
          </group>
          <group group_id="O4">
            <title>Dosage Tier 4</title>
            <description>25% human albumin 2.5 g/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events</title>
          <description>Serious adverse events included neurological and medical complications and neurological deterioration.
Neurological deterioration was defined as a decline by more than 2 points in the Glasgow Coma Scale.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Symptomatic Cerebral Vasospasm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary Edema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARDS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rebleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary Embolism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gram-Negative Ventriculitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypotension due to sepsis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Good Clinical Outcome Was Defined as a Glasgow Outcome Scale Score of 0-1</title>
        <description>Number of subjects with good clinical outcome defined as a Glasgw Outcome Scale score of 0-1</description>
        <time_frame>3 months after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dosage Tier 1</title>
            <description>25% human albumin 0.625 g/kg</description>
          </group>
          <group group_id="O2">
            <title>Dosage Tier 2</title>
            <description>25% human albumin 1.25 g/kg</description>
          </group>
          <group group_id="O3">
            <title>Dosage Tier 3</title>
            <description>25% human albumin 1.875 g/kg</description>
          </group>
          <group group_id="O4">
            <title>Dosage Tier 4</title>
            <description>25% human albumin 2.5 g/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Good Clinical Outcome Was Defined as a Glasgow Outcome Scale Score of 0-1</title>
          <description>Number of subjects with good clinical outcome defined as a Glasgw Outcome Scale score of 0-1</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Post-hoc comparison of outcomes in dosage tier 1 vs dosage tier 2.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>14.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dosage Tier 1</title>
          <description>25% human albumin 0.625 g/kg</description>
        </group>
        <group group_id="E2">
          <title>Dosage Tier 2</title>
          <description>25% human albumin 1.25 g/kg</description>
        </group>
        <group group_id="E3">
          <title>Dosage Tier 3</title>
          <description>25% human albumin 1.875 g/kg</description>
        </group>
        <group group_id="E4">
          <title>Dosage Tier 4</title>
          <description>25% human albumin 2.5 g/kg</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Severe or life-threatening acute heart failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypotension due to sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Gram-negative ventriculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Symptomatic Cerebral Vasospasm</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Rebleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ARDS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Our study has several limitations. ALISAH is an early phase design and we do not have concurrent controls. In addition, the study was neither randomized nor powered to test for efficacy effects.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jose I Suarez, MD, Professor of Neurology</name_or_title>
      <organization>Baylor College of Medicine</organization>
      <phone>713-798-8472</phone>
      <email>jisuarez@bcm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

